Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Wednesday 05 May, 2021

Tissue Regenix Group

Grant of share options

RNS Number : 5437X
Tissue Regenix Group PLC
05 May 2021
 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

Grant of share options

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, have each been granted an award of restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company ("Ordinary Shares") under the existing Tissue Regenix Share Incentive Plan.

 

Daniel Lee has been awarded 28,321,603 RSUs and David Cocke has been awarded 14,649,105 RSUs, where each RSU that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share. The RSUs are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets.

 

Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 28,321,603 and 14,649,105 RSUs respectively representing 0.4% and 0.2% of the current issued share capital respectively.

 

For more information:

 

Tissue Regenix Group plc

David Cocke, Chief Financial Officer

www.tissueregenix.com

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600

 

Walbrook PR Ltd

Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780

 [email protected]

 

 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

     1

 

Details of the person discharging managerial responsibilities / person closely associated    

a)

 

Name

Daniel Lee 

2

 

Reason for the notification

a)

 

Position/status

 

CEO

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

 

Tissue Regenix Group plc

b)

 

LEI

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p

b)

Identification code 

 

GB00B5SGVL29

c)

 

Nature of the transaction 

 

Issue of options

d)

 

Price(s) and volume(s)

Volume(s):

28,321,603 RSUs

Price: 0.1   pence per RSU

d)

 

Aggregated information 

- Aggregated volume

- Price

 

28,321,603

£28,321.60

e)

 

Date of the transactions 

4 May 2021

f)

 

Place of the transaction

Outside of a trading venue

 

     1

 

Details of the person discharging managerial responsibilities / person closely associated    

a)

 

Name

David Cocke 

2

 

Reason for the notification

a)

 

Position/status

 

CFO

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

 

Tissue Regenix Group plc

b)

 

LEI

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p

b)

Identification code 

 

GB00B5SGVL29

c)

 

Nature of the transaction 

 

Issue of options

d)

 

Price(s) and volume(s)

Volume(s):

14,649,105 RSUs

Price: 0.1   pence per RSU

d)

 

Aggregated information 

- Aggregated volume

- Price

 

14,649,105

£14,649.10

e)

 

Date of the transactions 

4 May 2021

f)

 

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKQBQDBKBOPK

a d v e r t i s e m e n t